Background: After conventionally fractionated radical radiotherapy for advanced unresectable squamous cell carcinoma of the tongue, the floor of mouth and the supraglottic larynx, oro- and hypopharynx loco-regional tumor control rates rarely exceed 30%. Therefore, cytotoxic chemotherapy has been added in an attempt to improve loco-regional tumor control rates and reduce the incidence of distant spread and ultimately long-term survival. Still, in these patients comorbidity may often compromise possible improvements achieved by treatment intensification. Patients and Methods: In a prospective phase II study from 1984 to 1989, patients with loco-regionally advanced head and neck carcinoma were treated with 3 courses of simultaneous radio-chemotherapy. Radiotherapy was administered in two fractions per day 1.8 Gy each. During one course from day 3 to day 11 23.4 Gy were delivered in 13 fractions. Chemotherapy consisted of cis-Platin 60 mg/m2, leucovorin 50 mg/m2 intravenous bolus and 5-FU 350 mg/m2 intravenous bolus on day 2 and leucovorin 100 mg/m2/24-hour continuous infusion and 5-FU 350 mg/m2/24 h from day 2 to 5. Treatment was repeated on days 22 and 44, total radiation dose was 70.2 Gy. From day 12 to 21 and 34 to 43 treatment breaks were scheduled. Results: 105 patients are evaluable with a follow-up from 36 to 105 months in surviving patients. The crude overall survival rate at 5 years is 29% the probability of progression-free survival is 39% (Kaplan-Meier estimations). Loco-regional recurrences were observed in 52 patients after a median interval of 11 (2-81) months. 16 patients developed distant metastases after a median interval of 21 (6-81) months. Conclusions: Compared with data from the literature the pattern of relapse is very similar to that observed after radical radiotherapy alone. Median interval to distant spread appears to be prolonged by simultaneous chemotherapy but this may be due to prolonged follow up. Three-year figures of loco-regional control and survival are valid parameters to apreciate long-term data. Since nearly a third of patients are long-term survivors chronic toxicity deserves special attention in future trials.

Keywords:
Head and neck cancer, Radiochemotherapy, Pattern of failure Distant metastases, Survival
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.